NASDAQ:TCRR

TCR2 Therapeutics - TCRR Stock Forecast, Price & News

$1.33

+0.07 (+5.56%)

(As of 11/30/2022 05:19 PM ET)

Add

Compare

Today's Range: $1.25
▼
$1.34
50-Day Range: $1.26
▼
$2.09
52-Week Range: $1.23
▼
$5.51

Volume: 138,150 shs
Average Volume: 429,185 shs
Market Capitalization: $51.41 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

TCR2 Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 724.0% Upside
$11.00 Price Target
Short Interest: Healthy
4.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.65
Upright™ Environmental Score
News Sentiment: 0.73
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.10) to ($2.37) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.66 out of 5 stars

Medical Sector

96th out of 1,043 stocks

Biological Products, Except Diagnostic Industry

12th out of 172 stocks

3.3

Analyst's Opinion

Consensus Rating
TCR2 Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, TCR2 Therapeutics has a forecasted upside of 724.0% from its current price of $1.34.
Amount of Analyst Coverage
TCR2 Therapeutics has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.02% of the float of TCR2 Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
TCR2 Therapeutics has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in TCR2 Therapeutics has recently decreased by 35.08%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
TCR2 Therapeutics does not currently pay a dividend.
Dividend Growth
TCR2 Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
TCR2 Therapeutics has received a 75.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for TCR2 Therapeutics is -0.65.

2.1

News and Social Media Coverage

News Sentiment
TCR2 Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for TCR2 Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
Only 2 people have added TCR2 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TCR2 Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
25.01% of the stock of TCR2 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
64.56% of the stock of TCR2 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for TCR2 Therapeutics are expected to grow in the coming year, from ($3.10) to ($2.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TCR2 Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TCR2 Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TCR2 Therapeutics has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About TCR2 Therapeutics (NASDAQ:TCRR) Stock

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Stock News Headlines

November 24, 2022 | americanbankingnews.com

Analysts Offer Predictions for TCR2 Therapeutics Inc.'s Q1 2023 Earnings (NASDAQ:TCRR)

November 23, 2022 | finance.yahoo.com

TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference

November 23, 2022 | americanbankingnews.com

HC Wainwright Analysts Lift Earnings Estimates for TCR2 Therapeutics Inc. (NASDAQ:TCRR)

November 23, 2022 | americanbankingnews.com

TCR2 Therapeutics (NASDAQ:TCRR) PT Lowered to $13.00

November 11, 2022 | finance.yahoo.com

Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)

November 8, 2022 | finanznachrichten.de

TCR2 Therapeutics: TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 8, 2022 | finance.yahoo.com

TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 7, 2022 | finance.yahoo.com

TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer

November 6, 2022 | finance.yahoo.com

Is TCR2 Therapeutics (NASDAQ:TCRR) In A Good Position To Deliver On Growth Plans?

September 28, 2022 | finance.yahoo.com

TCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesothelioma

September 28, 2022 | seekingalpha.com

TCR2 Therapeutics stock rises 16% as cell therapy for solid tumors shows promise in trial

September 28, 2022 | finance.yahoo.com

gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma

September 27, 2022 | finance.yahoo.com

TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors

September 26, 2022 | finance.yahoo.com

TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

August 19, 2022 | seekingalpha.com

TCR² Therapeutics: Betting On A Solid Reversal

August 8, 2022 | finance.yahoo.com

TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 8, 2022 | finance.yahoo.com

What Kind Of Shareholders Hold The Majority In TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) Shares?

August 8, 2022 | americanbankingnews.com

TCR2 Therapeutics Inc. (NASDAQ:TCRR) Given Average Rating of "Moderate Buy" by Brokerages

June 27, 2022 | marketwatch.com

TCR2 Therapeutics Names Eric Sullivan Chief Financial Officer >TCRR

June 27, 2022 | finance.yahoo.com

TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer

May 30, 2022 | finance.yahoo.com

Will TCR2 Therapeutics (NASDAQ:TCRR) Spend Its Cash Wisely?

May 12, 2022 | finance.yahoo.com

TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

March 24, 2022 | marketwatch.com

TCR2 Therapeutics Shares Rise 17% on 4Q Results, Trial Progress

March 22, 2022 | seekingalpha.com

TCR2 Therapeutics GAAP EPS of -$0.72 beats by $0.04

March 22, 2022 | finance.yahoo.com

TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Company Calendar

Last Earnings: 11/10/2021
Today: 11/30/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/28/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TCRR
CUSIP: N/A
CIK: 1750019
Web: www.tcr2.com
Phone: (617) 949-5200
Fax: N/A
Employees: 137
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.00
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +727.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-99,810,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -49.52%
Return on Assets: -38.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.02
Quick Ratio: 5.02

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.14 per share
Price / Book: 0.26

Miscellaneous

Outstanding Shares: 38,657,000
Free Float: 28,989,000
Market Cap: $51.41 million
Optionable: Not Optionable
Beta: 1.77

Key Executives

Dr. Garry E. Menzel M.B.A. (Age 58)
Ph.D., Pres, CEO & Director
Comp: $916.8k

Dr. Patrick A. Baeuerle Ph.D. (Age 64)
Founder & Member of the Advisory Board
Comp: $47.02k

Mr. Peter Olagunju (Age 44)
Chief Technical Officer
Comp: $307.42k

Dr. Alfonso Quintas Cardama M.D. (Age 51)
Chief Medical Officer
Comp: $668.6k

Mr. Richard Roomberg
VP of Corp. Controller

Mr. Eric M. Sullivan CPA (Age 42)
Chief Financial Officer

Carl Mauch
Sr. Director of Investor Relations & Corp. Communications

Ms. Margaret Siegel J.D.
Head of Legal & Corp. Sec.

Dr. Angela Justice Ph.D. (Age 48)
Chief People Officer

Dr. Rosemary Harrison Ph.D. (Age 39)
Chief Bus. & Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TCRR Stock - Frequently Asked Questions

Should I buy or sell TCR2 Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCRR shares.
View TCRR analyst ratings or view top-rated stocks.
What is TCR2 Therapeutics' stock price forecast for 2023?: 3 Wall Street analysts have issued twelve-month price objectives for TCR2 Therapeutics' shares. Their TCRR share price forecasts range from $5.00 to $18.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 720.9% from the stock's current price.
View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts.
How have TCRR shares performed in 2022?: TCR2 Therapeutics' stock was trading at $4.66 at the beginning of 2022. Since then, TCRR stock has decreased by 71.2% and is now trading at $1.34.
View the best growth stocks for 2022 here.
Are investors shorting TCR2 Therapeutics?: TCR2 Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 1,240,000 shares, a drop of 35.1% from the October 31st total of 1,910,000 shares. Based on an average daily trading volume, of 223,300 shares, the short-interest ratio is currently 5.6 days. Currently, 4.0% of the shares of the company are short sold.
View TCR2 Therapeutics' Short Interest.
When is TCR2 Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our TCRR earnings forecast.
How were TCR2 Therapeutics' earnings last quarter?: TCR2 Therapeutics Inc. (NASDAQ:TCRR) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.06.

What other stocks do shareholders of TCR2 Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).
When did TCR2 Therapeutics IPO?: (TCRR) raised $76 million in an IPO on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.
What is TCR2 Therapeutics' stock symbol?: TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."
Who are TCR2 Therapeutics' major shareholders?: TCR2 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Tang Capital Management LLC (9.68%), Vanguard Group Inc. (3.71%), BlackRock Inc. (2.65%), Renaissance Technologies LLC (1.83%), Two Sigma Advisers LP (1.02%) and Dimensional Fund Advisors LP (0.85%). Insiders that own company stock include Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson and Robert Hofmeister.
View institutional ownership trends.
How do I buy shares of TCR2 Therapeutics?: Shares of TCRR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is TCR2 Therapeutics' stock price today?: One share of TCRR stock can currently be purchased for approximately $1.34.
How much money does TCR2 Therapeutics make?: TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $51.80 million. The company earns $-99,810,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis.
How many employees does TCR2 Therapeutics have?: The company employs 137 workers across the globe.
How can I contact TCR2 Therapeutics?: TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com.

This page (NASDAQ:TCRR) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial